Emojia Biopharma's Mission and Focus

Emojia Biopharma, founded in 2019, aims to make car T cell therapies more accessible to a larger number of patients. The current process of delivering car T cell therapies involves a complex logistical procedure, which includes collecting T cells from a patient, shipping them to a central manufacturing facility for engineering, and then bringing them back to the patient. To simplify this process, Emojia Biopharma has developed lenniviral vector technology that can be delivered directly to the patient, allowing their body to perform all the manufacturing. This approach resembles a synthetic immune response or a genetic vaccine.